JP5416089B2 - ジアゾ二環式ｓｍａｃ模倣物およびその使用 - Google Patents
ジアゾ二環式ｓｍａｃ模倣物およびその使用 Download PDFInfo
- Publication number
- JP5416089B2 JP5416089B2 JP2010503269A JP2010503269A JP5416089B2 JP 5416089 B2 JP5416089 B2 JP 5416089B2 JP 2010503269 A JP2010503269 A JP 2010503269A JP 2010503269 A JP2010503269 A JP 2010503269A JP 5416089 B2 JP5416089 B2 JP 5416089B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- group
- apoptosis
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC([C@@](CC1)*2[C@@]1C(OC)=O)/C=*/C[C@](*CC*)C2=O Chemical compound CC([C@@](CC1)*2[C@@]1C(OC)=O)/C=*/C[C@](*CC*)C2=O 0.000 description 5
- UBTVVCSVUMFKAR-JCJIYJPFSA-N CC(C)CC(N(CC[C@@H](CC1)N2[C@@H]1C(NC(c1ccc(C)cc1)c(cc1)ccc1F)=O)C[C@H](CNC(C(C)C)=O)C2=O)=O Chemical compound CC(C)CC(N(CC[C@@H](CC1)N2[C@@H]1C(NC(c1ccc(C)cc1)c(cc1)ccc1F)=O)C[C@H](CNC(C(C)C)=O)C2=O)=O UBTVVCSVUMFKAR-JCJIYJPFSA-N 0.000 description 1
- JRPFGUVEGUMVRX-LQBCTSRJSA-N CC(C)CCCC(N(CC[C@@H](CC[C@H]1C(NC(c2ccccc2)c2ccccc2)=O)N1C1=O)C[C@@H]1NC([C@H](C)NC)=O)=O Chemical compound CC(C)CCCC(N(CC[C@@H](CC[C@H]1C(NC(c2ccccc2)c2ccccc2)=O)N1C1=O)C[C@@H]1NC([C@H](C)NC)=O)=O JRPFGUVEGUMVRX-LQBCTSRJSA-N 0.000 description 1
- FQSPQHRWQMGKNA-MQWKRIRWSA-N COC([C@H]1NC(CC=C)CC1)=O Chemical compound COC([C@H]1NC(CC=C)CC1)=O FQSPQHRWQMGKNA-MQWKRIRWSA-N 0.000 description 1
- OYFYMHHWDKFDNK-JBKTXMORSA-N C[C@@H](C(N[C@@H](CN(CC[C@@H](CC1)N2[C@@H]1C(NC(c1ccccc1)c1ccccc1)=O)C(C[C@H]1COCC1)=O)C2=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](CN(CC[C@@H](CC1)N2[C@@H]1C(NC(c1ccccc1)c1ccccc1)=O)C(C[C@H]1COCC1)=O)C2=O)=O)NC OYFYMHHWDKFDNK-JBKTXMORSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92334807P | 2007-04-13 | 2007-04-13 | |
| US60/923,348 | 2007-04-13 | ||
| PCT/US2008/060215 WO2008128171A2 (en) | 2007-04-13 | 2008-04-14 | Diazo bicyclic smac mimetics and the uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523722A JP2010523722A (ja) | 2010-07-15 |
| JP2010523722A5 JP2010523722A5 (enExample) | 2012-04-19 |
| JP5416089B2 true JP5416089B2 (ja) | 2014-02-12 |
Family
ID=39864640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503269A Expired - Fee Related JP5416089B2 (ja) | 2007-04-13 | 2008-04-14 | ジアゾ二環式ｓｍａｃ模倣物およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8278293B2 (enExample) |
| EP (1) | EP2139490B1 (enExample) |
| JP (1) | JP5416089B2 (enExample) |
| KR (1) | KR101081685B1 (enExample) |
| CN (1) | CN101686981B (enExample) |
| AU (1) | AU2008240119B2 (enExample) |
| BR (1) | BRPI0810522B8 (enExample) |
| CA (1) | CA2683318C (enExample) |
| CY (1) | CY1115735T1 (enExample) |
| DK (1) | DK2139490T3 (enExample) |
| EA (1) | EA017797B1 (enExample) |
| ES (1) | ES2504216T3 (enExample) |
| HR (1) | HRP20140885T1 (enExample) |
| HU (1) | HUE024142T2 (enExample) |
| IL (1) | IL201474A (enExample) |
| MX (1) | MX2009011069A (enExample) |
| NZ (1) | NZ580468A (enExample) |
| PL (1) | PL2139490T3 (enExample) |
| PT (1) | PT2139490E (enExample) |
| SI (1) | SI2139490T1 (enExample) |
| WO (1) | WO2008128171A2 (enExample) |
| ZA (1) | ZA200907055B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| ES2643233T3 (es) | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| CA2780130A1 (en) * | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| AU2013306087B2 (en) * | 2012-08-23 | 2017-08-10 | The Regents Of The University Of Michigan | Bivalent inhibitors of IAP proteins and therapeutic methods using the same |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MX2016001654A (es) | 2013-09-09 | 2016-05-02 | Halliburton Energy Services Inc | Activacion de composiciones de cemento con retardo de fraguado mediante el intercambio de retardante. |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6768522B2 (ja) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AU2017253560B2 (en) | 2016-04-20 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| US20210154184A1 (en) | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| KR20200072507A (ko) | 2017-10-19 | 2020-06-22 | 데비오팜 인터네셔날 에스 에이 | 암 치료를 위한 조합 제품 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019177902A1 (en) | 2018-03-10 | 2019-09-19 | Yale University | Modulators of btk proteolysis and methods of use |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| US20200038513A1 (en) | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| CN119219628A (zh) | 2018-09-07 | 2024-12-31 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法 |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| JP2022511437A (ja) | 2018-11-26 | 2022-01-31 | デバイオファーム インターナショナル エス．エー． | Ｈｉｖ感染の組み合わせ治療 |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| EP3911316A1 (en) | 2019-01-17 | 2021-11-24 | Debiopharm International SA | Combination product for the treatment of cancer |
| ES3055186T3 (en) | 2019-04-04 | 2026-02-10 | Dana Farber Cancer Inst Inc | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| CN110028508B (zh) * | 2019-05-16 | 2021-05-28 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| AU2020356356A1 (en) | 2019-09-25 | 2022-05-12 | Debiopharm International S.A. | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| US12678509B2 (en) | 2019-11-08 | 2026-07-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (IAP) protein antagonists |
| US20230056604A1 (en) | 2020-01-20 | 2023-02-23 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2022183006A1 (en) | 2021-02-25 | 2022-09-01 | Mayo Foundation For Medical Education And Research | Compounds for programmable protein degradation and methods of use for the disease treatment |
| EP4308095A4 (en) | 2021-03-15 | 2025-02-19 | Maze Therapeutics, Inc. | GLYCOGEN SYNTHASE 1 (GYS1) INHIBITORS AND METHODS OF USE THEREOF |
| WO2024022275A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| AR131299A1 (es) * | 2022-12-09 | 2025-03-05 | Debiopharm Int Sa | Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2026006700A1 (en) * | 2024-06-28 | 2026-01-02 | Regents Of The University Of Michigan | Pyrrolo[1,2-a]-azocine analogues as iap antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| WO2003013571A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| BRPI0506883A (pt) * | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| WO2006010119A2 (en) | 2004-07-09 | 2006-01-26 | Michael Norris | Cargo retaining device for use in vehicle cargo storage areas |
| WO2006010118A2 (en) * | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| ES2525585T3 (es) * | 2006-05-05 | 2014-12-26 | The Regents Of The University Of Michigan | Intermedios para la preparación de miméticos de SMAC bivalentes |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| US8445473B2 (en) * | 2008-04-11 | 2013-05-21 | The Regents Of The University Of Michigan | Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof |
| US8625740B2 (en) * | 2011-04-14 | 2014-01-07 | Morpho Detection, Inc. | System and method for correcting X-ray diffraction profiles |
-
2008
- 2008-04-14 WO PCT/US2008/060215 patent/WO2008128171A2/en not_active Ceased
- 2008-04-14 CN CN2008800186484A patent/CN101686981B/zh not_active Expired - Fee Related
- 2008-04-14 CA CA2683318A patent/CA2683318C/en active Active
- 2008-04-14 EA EA200901400A patent/EA017797B1/ru unknown
- 2008-04-14 AU AU2008240119A patent/AU2008240119B2/en not_active Ceased
- 2008-04-14 US US12/159,249 patent/US8278293B2/en active Active
- 2008-04-14 PL PL08745750T patent/PL2139490T3/pl unknown
- 2008-04-14 KR KR1020097023384A patent/KR101081685B1/ko not_active Expired - Fee Related
- 2008-04-14 HU HUE08745750A patent/HUE024142T2/en unknown
- 2008-04-14 SI SI200831285T patent/SI2139490T1/sl unknown
- 2008-04-14 EP EP08745750.3A patent/EP2139490B1/en active Active
- 2008-04-14 MX MX2009011069A patent/MX2009011069A/es active IP Right Grant
- 2008-04-14 HR HRP20140885AT patent/HRP20140885T1/hr unknown
- 2008-04-14 BR BRPI0810522A patent/BRPI0810522B8/pt not_active IP Right Cessation
- 2008-04-14 DK DK08745750.3T patent/DK2139490T3/da active
- 2008-04-14 NZ NZ580468A patent/NZ580468A/en not_active IP Right Cessation
- 2008-04-14 ES ES08745750.3T patent/ES2504216T3/es active Active
- 2008-04-14 JP JP2010503269A patent/JP5416089B2/ja not_active Expired - Fee Related
- 2008-04-14 PT PT87457503T patent/PT2139490E/pt unknown
-
2009
- 2009-10-09 ZA ZA2009/07055A patent/ZA200907055B/en unknown
- 2009-10-12 IL IL201474A patent/IL201474A/en active IP Right Grant
-
2012
- 2012-07-25 US US13/557,804 patent/US8664212B2/en not_active Expired - Fee Related
-
2014
- 2014-09-29 CY CY20141100792T patent/CY1115735T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5230610B2 (ja) | 二価ｓｍａｃ模倣物およびその使用 | |
| JP2010523722A (ja) | ジアゾ二環式ｓｍａｃ模倣物およびその使用 | |
| CN102627649B (zh) | Mdm2的小分子抑制剂以及其应用 | |
| WO2006010118A2 (en) | Conformationally constrained smac mimetics and the uses thereof | |
| EP2265604A2 (en) | Heteroaryl-substituted bicyclic smac mimetics and the uses thereof | |
| JP2007522116A (ja) | コンホメーションが制約されたＳｍａｃ模倣物およびその使用 | |
| WO2005069888A2 (en) | Smac peptidomimetics and the uses thereof | |
| KR100887045B1 (ko) | 구조적으로 강제된 ｓｍａｃ 유사물 및 이들의 용도 | |
| HK1141456B (en) | Diazo bicyclic smac mimetics and the uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110405 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130415 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130709 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130919 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131024 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5416089 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |